Shimoni A - Search Results

1

Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.

Fried S, Shouval R, Varda-Bloom N, Besser MJ, Yerushalmi R, Shem-Tov N, Danylesko I, Jacoby E, Teihman S, Itzhaki O, Fein JA, Kedmi M, Shimoni A, Nagler A, Avigdor A. Fried S, et al. Among authors: shimoni a. Leuk Lymphoma. 2022 Dec;63(14):3385-3393. doi: 10.1080/10428194.2022.2123232. Epub 2022 Sep 16. Leuk Lymphoma. 2022. PMID: 36111694

2

Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations.

Shimoni A, Nagler A. Shimoni A, et al. Leukemia. 2001 Dec;15(12):1967-75. doi: 10.1038/sj.leu.2402316. Leukemia. 2001. PMID: 11753620 Review. No abstract available.

3

Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.

Shimoni A, Nagler A. Shimoni A, et al. Cancer Treat Res. 2002;110:113-36. doi: 10.1007/978-1-4615-0919-6_6. Cancer Treat Res. 2002. PMID: 11908195 Review.

4

Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders.

Shimoni A, Nagler A. Shimoni A, et al. Isr Med Assoc J. 2002 Apr;4(4):272-9. Isr Med Assoc J. 2002. PMID: 12001702 Free article. Review. No abstract available.

5

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.

Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshurun M, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L. Shimoni A, et al. Leukemia. 2002 Aug;16(8):1413-8; discussion 1419-22. doi: 10.1038/sj.leu.2402581. Leukemia. 2002. PMID: 12145678

6

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.

Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Leukemia. 2003 Feb;17(2):290-7. doi: 10.1038/sj.leu.2402808. Leukemia. 2003. PMID: 12592325 Clinical Trial.

7

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.

Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Exp Hematol. 2003 May;31(5):428-34. doi: 10.1016/s0301-472x(03)00047-x. Exp Hematol. 2003. PMID: 12763142 Free article.

8

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A. Shimoni A, et al. Br J Haematol. 2003 Aug;122(3):457-64. doi: 10.1046/j.1365-2141.2003.04446.x. Br J Haematol. 2003. PMID: 12877674 Free article.

9

Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning.

Shimoni A, Nagler A. Shimoni A, et al. Acta Haematol. 2004;112(1-2):93-104. doi: 10.1159/000077564. Acta Haematol. 2004. PMID: 15179009 Review.

10

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.

Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Biol Blood Marrow Transplant. 2004 Jul;10(7):484-93. doi: 10.1016/j.bbmt.2004.03.002. Biol Blood Marrow Transplant. 2004. PMID: 15205669 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

247 results

Search Page

Filters